Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Infant formula suitable for intestinal lymphangiectasia

An infant formula and lymphatic vessel technology, applied in applications, dairy products, dairy products, etc., can solve problems such as dietary transition, protein intolerance, and adverse effects of children returning to normal lifestyles in a timely manner. , to achieve effective recovery of digestive system function, improve prognosis, good growth and development effect

Inactive Publication Date: 2017-06-13
BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The nutritional treatment of the disease at home and abroad is mainly based on short-chain fatty acids (MCT) instead of long-chain fatty acids (common cooking oil). For infants and young children who are breast-feeding, MCT oil combined with skimmed milk powder is the main method of feeding. , there has been a lack of standardized nutritional treatment methods and corresponding personalized formula milk
At the same time, diarrhea that cannot be effectively corrected is often misdiagnosed as protein intolerance, and the choice of hydrolyzed protein formula based on amino acids or amino acid short peptides as the main nitrogen form affects the effective recovery of the disease and the dietary transition after recovery.
Therefore, although the disease is effectively controlled, the child is kept in an abnormal diet for a long time, causing long-term potential adverse effects on the child's return to a normal lifestyle in time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Infant formula suitable for intestinal lymphangiectasia
  • Infant formula suitable for intestinal lymphangiectasia
  • Infant formula suitable for intestinal lymphangiectasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Embodiment 1, preparation formula milk powder

[0073] The composition of 100g formula milk powder is as follows:

[0074] Carbohydrates 60.0g, of which, lactose 35.0g, maltodextrin 23.0g, fructooligosaccharides 2.0g;

[0075] Protein 18.0g, including whey protein 14.0g, casein 3.995g, phosphatidylseramide peptide 5.0mg;

[0076] Lipids 19.744g, of which, MCT18.424g, EPA30.0mg, DHA30.0mg, linolenic acid 440mg, linoleic acid 940mg, oleic acid 500mg, arachidonic acid 60.0mg, lecithin 70.0mg, cephalin 80.0mg, bovine Sulfonic acid 30.0mg, inositol 15.0mg, nucleotide 20.0mg, immunoglobulin (IgA) 35.0mg;

[0077] Vitamins and minerals 2.256g, of which, vitamin A200μg, vitamin D5.0μg, vitamin E3.0mg, vitamin K10.0μg, vitamin 50.0mg, vitamin B10.5mg, vitamin B20.5mg, vitamin B60.5mg, vitamin B121.0μg , Niacin 4.0mg, Folic Acid 100.0mg, Pantothenic Acid 2.0μg, Biotin 10.0μg, Choline 120mg, Sodium 100mg, Potassium 400mg, Copper 150mg, Magnesium 65.0mg, Iron 8.0mg, Zinc 4.0mg, ...

Embodiment 2

[0080] Embodiment 2, the clinical application of formula milk powder of the present invention

[0081] The formula milk powder (whole protein formula) of the present invention is combined with other A formula milk powder (pre-digestion auxiliary formula) and / or B formula milk powder (partial pre-digestion formula) for the clinical nutrition of primary infant small intestinal lymphangiectasia Treatment, formula milk powder of the present invention is recorded as C formula milk powder.

[0082] The composition of 100gA formula milk powder is as follows:

[0083] Carbohydrate 75.0g, of which, lactose 35.0g, maltodextrin 37.5g, fructooligosaccharide 2.5g;

[0084] Protein 12.742g, of which, phosphatidylseramide peptide 5.0mg, the balance is short peptides 12.737g;

[0085] Lipids 10.002g, of which, MCT8.682g, EPA30.0mg, DHA30.0mg, linolenic acid 250mg, linoleic acid 500mg, oleic acid 200mg, arachidonic acid 60.0mg, lecithin 70.0mg, cephalin 80.0mg, bovine Sulfonic acid 30.0mg, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an infant formula suitable for intestinal lymphangiectasia (IL). Every 100g of the infant formula consists of the following components: 55.0-65.0g of carbohydrate, 15.0-20.0g of protein, 15.0-20.0g of lipids and the balance of vitamin and mineral, wherein the carbohydrate is a mixture of maltodextrin and fructo-oligosaccharide or a mixture of lactose, maltodextrin and fructo-oligosaccharide. Through strict low LCT / gradual MCT replaced enteral nutrition and dietary therapy, a children patient grows and develops well, the functions of the digestive system are effectively recovered, the indexes all recover to normal level or reach the clinical cure standard, the symptoms are effectively controlled, the prognosis of IL is greatly improved, and theoretical and practical basis is provided for standard treatment on infant primary IL.

Description

technical field [0001] The invention relates to a milk powder, in particular to an infant formula milk powder suitable for primary small intestinal lymphangiectasia. Background technique [0002] Intestinal lymphangiectasia (IL) is a rare protein-losing enteropathy. It is a kind of expansion and rupture of small intestinal lymphatic vessels caused by various reasons, resulting in protein, fat, immune cells, etc. A rare disease in which a large amount of material is lost (Lee J, Kong MS. Primary intestinallymphiectasia diagnosed by endoscopy following the intake of a high-fat meal. Eur JPediatr. 2008; 167(2): 237-239. Liu NF, Lu Q, Wang CG , et al. Magnetic cresonance imaging as a new method to diagnose protein-losing enteropathy. Lymphology. 2008; 41(3): 111-115.). The clinical manifestations mainly include severe hypoproteinemia, decreased blood lymphocytes, edema, celiac ascites, diarrhea, etc. (Jie Wen, Qingya Tang, Jiang Wu, Ying Wang, WeiCai. Primary Intestinal Lymphan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A23C9/152
Inventor 李素云吉琳琳刘晋王立芹贺源刘晓倩李茜玉沈文斌陈葵冯欢霞
Owner BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products